Michael Makris/LinkedIn
Apr 17, 2026, 14:43
Michael Makris: Are Rebalancing Agents in Hemophilia Associated with Thrombosis?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about his recent article, published in the Journal of Thrombosis and Haemostasis։
”The PDF of my Forum article on the potential thrombogenicity of the ‘rebalancing’ agents is now available on the Journal of Thrombosis and Haemostasis website.”
Title: How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Author: Michael Makris
Other posts featuring Michael Makris on Hemostasis Today.
-
Jul 21, 2026, 15:02Sham Zamil: The Role of ABO Compatibility in Platelet Pooling
-
Jul 21, 2026, 13:43Dima Shulkin: Assessing AI-Driven Blood Test Screening for Colorectal Cancer
-
Jul 21, 2026, 13:24Benoit Mores: National Initiative Targets Better Cardiovascular Outcomes
-
Jul 21, 2026, 13:10Paolo Zamboni: Chronic Cerebrospinal Venous Insufficiency Hypothesis in Multiple Sclerosis
-
Jul 21, 2026, 13:05Danai Poutakidou։ The Diagnostic Pitfalls of Unexpected PT/INR Prolongation
-
Jul 21, 2026, 13:00Kefah Mokbel: Beyond Thromboprophylaxis – Enoxaparin’s Emerging Anticancer Signal
-
Jul 21, 2026, 12:56Emmanuel Velazquez-Alvarez: Bridging Innovation and Clinical Practice
-
Jul 21, 2026, 12:53Sandrine Bouteille: A Milestone Presentation at ISTH 2026
-
Jul 21, 2026, 12:40Kalled Musallam: A Comprehensive Review of Thalassemia